MSCI's InvestorForce to Merge with Investment Metrics

InvestorForce will merge with Investment Metrics and aim to expand European and Asian footprint.

mergers-idm0517

With the acquisition, Resurgens will merge MSCI’s InvestorForce with Investment Metrics, one of its portfolio companies. The transaction is expected to close in the next three months.

Both InvestorForce and Investment Metrics provide analytics and reporting software to institutional investment consultants, wealth managers and asset managers for multiple asset classes.

The merged company will operate under the Investment Metrics name and continue to support offerings of both firms. Its clients

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Waterstechnology? View our subscription options

‘Feature, not a bug’: Bloomberg makes the case for Figi

Bloomberg created the Figi identifier, but ceded all its rights to the Object Management Group 10 years ago. Here, Bloomberg’s Richard Robinson and Steve Meizanis write to dispel what they believe to be misconceptions about Figi and the FDTA.

Where have all the exchange platform providers gone?

The IMD Wrap: Running an exchange is a profitable business. The margins on market data sales alone can be staggering. And since every exchange needs a reliable and efficient exchange technology stack, Max asks why more vendors aren’t diving into this space.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here